These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Clinical observation on treatment of active systemic lupus erythematosus with haoqin qingdan decoction].
    Author: Liu W, Wang H, Yang XY.
    Journal: Zhongguo Zhong Xi Yi Jie He Za Zhi; 2006 May; 26(5):448-50. PubMed ID: 16883916.
    Abstract:
    OBJECTIVE: To observe the therapeutic efficacy and safety of Haoqin Qingdan Decoction (HQD) in treating active stage of systemic lupus erythematosus (SLE). METHODS: One hundred and twenty patients with SLE were randomly assigned into two groups, the treated group receiving HQD and prednisone, and the control group receiving prednisone and cyclophosphamide (CTX), both were treated for 3 months. SLE disease activity index (SLEDAI), various immunological indexes, blood and urine routine, hepatic and renal function, as well as the other adverse reaction of the treatment were observed. RESULTS: The total effective rate in the treated group was 81.67% (49/60), while 76.67% (46/60) in the control group, showing insignificant difference between the two groups. SLEDAI, erythrocyte sedimentation rate (ESR), complement 3 (C3), 24-hr urinary protein excretion and anti-double strain deoxyribonucleic acid (dsDNA) antibody were improved in the treated group, and no obvious adverse reaction was shown. CONCLUSION: HQD is obviously more effective in treating active stage of SLE with high safety.
    [Abstract] [Full Text] [Related] [New Search]